Table 3

Association of neutralising capacity and anti-RBD-IgG concentration with selected covariates in univariate and multivariable analyses (n=64)

Univariate analysisMultivariable analysis
RR*P value95% CIAUCRR*P value95% CI
Outcome: anti-RBD-IgG concentration >1 S/CO
 Female1.180.2800.88 to 1.580.601.230.1250.94 to 1.62
 Age (years)† 0.93 <0.001 0.89 to 0.97 0.89 0.94 0.001 0.90 to 0.97
 MTX monotherapy1.000.631.00
 MTX+prednisolone0.790.2840.51 to 1.220.860.4150.60 to 1.24
 MTX combination±prednisolone1.050.6870.84 to 1.301.040.6930.86 to 1.25
 MTX dose (mg)0.990.6880.97 to 1.020.54
 MTX-hold 1.39 0.006 1.10 to 1.76 0.74 1.27 0.020 1.04 to 1.56
 Vaccine interval 1.006 0.016 1.001 to 1.010 0.75 1.004 0.024 1.0006 to 1.008
Outcome: neutralisation capacity ≥30%
 Female1.360.0550.99 to 1.870.72 1.43 0.012 1.08 to 1.90
 Age (years)† 0.96 0.008 0.92 to 0.99 0.77 0.96 0.018 0.93 to 0.99
 MTX monotherapy1.000.681.00
 MTX+prednisolone0.750.1940.49 to 1.150.750.0990.53 to 1.06
 MTX combination±prednisolone1.040.6410.87 to 1.250.980.8380.84 to 1.15
 MTX dose (mg)0.990.4520.97 to 1.010.58
 MTX-hold 1.28 0.019 1.04 to 1.57 0.72 1.17 0.039 1.00 to 1.38
 Vaccine interval1.0020.2350.999 to 1.0060.631.0010.4230.998 to 1.004
  • *RR was estimated by a Poisson generalised linear model with robust error variances and log link function in univariate and multivariable analyses according to Zou.19

  • †RR for increase by 5 years.

  • AUC, area under the curve; MTX, methotrexate; RR, relative risk; S/CO, signal/cut-off.